Generic Injectables Market
Generic Injectables Market by Product Type (Large Molecule Injectables, mAb Generic Injectables, Insulin Generic Injectables), by Application (Oncology, Cardiology), by Container Type (Vials, Ampoules Premix, Prefilled syringes) by Region - Global insights 2022-2032
Analysis of Generic Injectables market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Generic Injectables Industry Insights (2022-2032)
The global generic injectables market is likely to be valued at US$ 1.02 Billion in FY 2022, up from US$ 0.8 Billion in 2021. During the past year, the industry registered a Y-o-Y increase worth 13.1%. From 2022 to 2032, Generic Injectables sales are poised to flourish at a CAGR of 13.3% to reach a value of US$ 3.6 Billion by the end of 2032.
|
Report Attributes |
Details |
|
Anticipated Base Year Value (2021) |
US$ 800 Million |
|
Expected Market Value (2022) |
US$ 1.02 Billion |
|
Projected Forecast Value (2032) |
US$ 3.6 Billion |
|
Global Growth Rate (2022-2032) |
13.3% CAGR |
|
Growth Rate of the U.S Market (2022-2032) |
11.5% CAGR |
|
Expected Market Value of China (2032) |
US$ 20.8 Billion (Approx.) |
|
U.K Market Expansion Rate (2022-2032) |
14.3% CAGR |
|
Key Companies Profiled |
|
The global market for Generic Injectables is poised to yield absolute dollar growth worth US$ 3.5 Million by 2032. Demand for Large Molecular injectables will continue to thrive, with a documented CAGR of 34.8% during the 2015-2021 historical period of assessment, while demand for Generic Injectables in Oncology proliferated at a rate of 11.5% during the same period. The APAC will dominate the global market, registering a growth opportunity worth US$ 20.8 Million from 2022 to 2032.
Fact.MR estimates that the global Generic Injectables industry is projected to grow at a CAGR of 13.3% from 2022 to 2032, generic injectables in cardiology are poised to witness a dexterous 13.1% CAGR.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
2015 to 2021 Generic Injectables Market Revenue Analysis vs. Market Outlook 2022-2032
Fact.MR has predicted the Generic Injectables market to upswing at 13.3% CAGR between 2022 and 2032 in comparison to the 11.3% CAGR throughout the historic period. The rising number of cancer patients has augmented the need to use generic formulae to develop affordable and quality drugs across the globe.
In recent years, demand for generic drugs has seen a prolific rise. High developmental and investment costs associated with branded formulations have prompted key players to invest in alternative formulae which are more affordable and accessible to people, especially in the developing world.
Key Drivers Stimulating Generic Injectables Industry Expansion
Prevalence of Chronic Diseases & Cheaper Manufacturing Cost to Push Demand
The global generic sterile injectable market is principally propelled by the mounting prevalence of several chronic diseases like cancer, diabetes, and the increasing geriatric population across the globe.
The old age people are more prone to numerous diseases and spend more on healthcare, thus impelling the growth of the generic sterile injectable market. According to a report by International Agency for Research on Cancer, nearly 19.3 billion new cases of cancer and 10 billion cancer death were testified in 2021.
Moreover, governments in several countries are reassuring the dispersal and development of generic drugs to make them available to a larger populace, particularly rural people in emerging countries.
Developing branded formulations is a time-consuming and expensive process. The average time required to develop a new chemical entity is a decade. A cost of US$ 5-8 Billion is incurred in the development of drug formulations, owing to stringent government regulations that ensure the safety and efficacy of preclinical and clinical trials.
In comparison, the development of generic drugs is an inexpensive process. This is because they are exempted from the requirement to conduct clinical trials and toxicity studies.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Key Challenges to Generic Injectables Industry Expansion
Shortage of Raw Material & Intensifying Shipping Expenses Restrains the Market Expansion
Several regions across the world have expressed concerns over the supply of generic injectable biosimilars running short. This is attributed to the reduced availability of international air transportation and a significant increase in shipping expenses.
Shortage of supply for numerous critical medicines, especially the injectable form of drugs that are mainly used in cancer chemotherapy, is a foremost problem faced globally. Due to constant scarcities, patients are unable to gain access to basic life-saving drugs, and this dearth is likely to sternly affect the expansion of the market.
The causes for the shortage of drugs are swelling manufacturing issues like the induction of particulate matter in the vials, equipment failures, and fungal or bacterial contaminations, postponement in supply owing to unavailability of raw material to begin drug manufacture, and shortage of active pharmaceutical ingredients (API).
Countries such as the United States have pointed out that a reduction in the availability of international shipping will prove expensive, particularly for critical medicines. Rising shipping costs are anticipated to prove detrimental to the operations of smaller companies, as well as consumers who depend on these drugs for their health problems.
Nevertheless, there exists a silver lining in the generic injectables market. Generic-drug pricing may leverage in the short-run, owing to scarcity created by supply-chain disruptions. This will prompt consumers to pay a higher price for the drugs in the long run to secure their supply.
Country-wise Analysis
How Opportunistic are Growth Prospects across the U.S Market?
Growing Emphasis on Clinical Trails likely to Fortify Demand
North America is projected to be the second-most lucrative market for generic injectables. This is mostly because of an increase in the number of abbreviated new drug application (ANDA) approvals, rising demand for inexpensive biosimilar products, and rising prevalence of lifestyle diseases. Fact.MR estimates that the valuation of the generic injectables market is likely to reach US$ 250 Million by 2032 which evaluated nearly US$ 75 Million in 2021. Projections indicate a robust CAGR of 11.4% during the forecast period.
Several prominent players are strengthening their positions in the region with augmented emphasis on clinical trials and through the introduction of several generic injectable drugs for critical diseases like cancer and diabetes.
For instance, Pfizer Inc. has recently partnered with Eli Lilly and Company, an American pharmaceutical company, to announce the approval of tanezumab, a generic injectable drug for treating osteoarthritis pain in the United States. With more proprietary drugs coming off patent in the approaching years, Pfizer has a far-sighted plan to develop generic versions of those injectables and acquire FDA consent to bring them to market.
Why are Generic Injectables Providers Venturing into Asia Pacific?
Asia-Pacific Remains the Kingpin in the Generic Injectables Industry
Asia-Pacific shows prolific growth opportunities for the global generic injectables market throughout the forecast period. High demand for injectable antibiotics in the wake of the high prevalence of infectious diseases such as diarrhea, typhoid, malaria, and cholera; increasing prevalence of cancer; high demand for inexpensive medicines, and a large market presence by key players are anticipated to leverage the growth in the Asia-Pacific.
Prominent Manufacturers of generic medicines are exploring the untapped potential for the prefilled syringes market in countries like Japan, Australia, China, and India. Besides, with the fiery upsurge in the population, the demand for syringes will flourish even further with the amplified consumption of vaccines. According to National Health Commission (NHC), China has been depending largely on generic medicines; out of ~170,000 drug approvals allotted by the China FDA, over 93% are generics.
In India, Cardiovascular diseases are considered the most common cause of death. The snowballing rate of heart diseases, linked with the expansion of the pharmaceutical sector, is compelling the market growth in the country. The treatment of cardiovascular diseases includes nanoparticle-based drug delivery as an ideal therapeutic alternative. This aspect is also responsible for augmenting the growth of the injectable drug delivery system in the region.
Fact.MR projections indicate a staggering CAGR of 16.1%, capturing a market share of almost two-fifths of the overall global generic injectables market. The latest analytical report summarizes that the market evaluated nearly US$ 4.1 Million in 2021 which is likely to expand to US$ 20.8 Million by the end of the projection period.
Country-wise Value CAGRs for Generic Injectables (2022-2032)
|
U. S |
11.5% |
|
U. K |
12.1% |
|
China |
16.1% |
|
Japan |
15.3% |
|
South Korea |
12.4% |
Category-wise Insights
Which Product Type is Most Preferred in the Generic Injectables Market?
Large Molecular Injectables to Register Stellar Growth in Upcoming Future
The large molecular injectables segment is projected to capture lion’s share in the global generic injectables market, accounting for 3/5th of the total market value. Large molecular injectable drugs are anticipated to expand at a stellar CAGR of 14.8% during the forecast period.
At the same time, the small molecular injectables segment shall hold a little over two-fifth of the generic injectables market. An increase in the incidence of infectious diseases in developing countries, greater affordability, and easy availability are key growth influencers. Moreover, the small molecular injectable drugs have widespread usage in the treatment of oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases.
By Application, which Generic Injectables are expected to Dominate?
Increasing Prevalence & Expensive Cost of Cancer Treatment Offers Significant Boost in Generic Therapeutics Demand
Based on the Application, the oncology segment captures nearly 30% share in the global generic injectables. The global generic oncology sterile injectable market size is estimated at nearly US$ 11.4 Million in 2019 and is expected to surpass the US$ 42 Million mark through 2032, witnessing a CAGR of 11.5% over the forecast period. Key manufacturers in the U.S. are concentrating on launching novel products to bargain low-cost treatments for patients.
The growth of the global Oncology Generic Injectable Drugs Market is mainly attributed to aspects such as patent expiry, rising incidence, and pervasiveness of cancer all over the world. Other reasons for the market growth comprise growing demand for generic injectables in developing countries owing to their low cost, combined with availability without prescription and a mounting number of patients undertaking chemotherapy worldwide.
Favorable governmental regulations to provide better treatment for the diseases like cancer in hospitals have boosted the generic therapeutics demand in the oncology sector. Since the cost of conventional treatment is highly expensive for such diseases, thereby there has been an increased emphasis on generic therapies for the treatment of cancer.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Prominent generic injectables providers are reliant on partnerships, collaborations, acquisitions, and new software launches to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.
- In April 2022, Hospira, Inc., the world leader in generic injectable pharmaceuticals, announced the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 Billion.
- Recently, The Buena, NJ-based company paid AstraZeneca $500,000 in cash for 18 products, 17 injectables, and one topical, and will make milestone payments of up to $6 Billion. The company also paid a royalty of nearly $3 Billion in Feb 2022.
Key Segments Covered in the Generic Injectables Industry Survey
-
Generic Injectables by Product type
- Large Molecule Injectables
- mAb Generic Injectables
- Insulin Generic Injectables
- Other Generic Injectables
- Small Molecule Injectables
-
Generic Injectables by Application
- Generic Injectables for Oncology
- Generic Injectables for Infectious Disease
- Generic Injectables for Cardiology
- Generic Injectables for Diabetes
- Generic Injectables for Immunology
- Others
-
Generic Injectables by Container Type
- Vials
- Ampoules
- Premix
- Prefilled syringes
- Other
-
Generic Injectables by Region
- North America Generic Injectables Market
- Latin America Generic Injectables Market
- Europe Generic Injectables Market
- Asia Pacific Generic Injectables Market
- Middle East & Africa Generic Injectables Market
Table of Content
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Assumptions and Acronyms Used 2.2. Research Methodology 3. Executive Summary 3.1. Global Generic Injectable Market Size (US$ Mn) and Forecast, by Region, 2022 and 2032 3.2. Global Generic Injectables Market: Market Snapshot 4. Market Overview 4.1. Global Generic Injectables Market Overview 4.2. Global Generic Injectables Market Key Industry Developments 5. Market Dynamics 5.1. Drivers and Restraints Snapshot Analysis 5.2. Drivers 5.3. Restraints 5.4. Opportunities 5.5. Key Trends 5.6. Global Generic Injectables Market Revenue Projections (US$ Mn), 2022-2032 5.7. Global Generic Products Penetration Overview: by Key Countries 5.8. Biosimilars: Pipeline Analysis 5.9. Generic Injectables Market: Mergers & Acquisitions 5.10. EU and USFDA Approved Biosimilar Products Snapshot 5.11. Challenges Faced by Biosimilar Product to be approved in U.S. Market 5.12. Regulatory Framework 5.13. Heat Map Analysis - Company 6. Global Generic Injectables Market Analysis, by Product Type 6.1. Introduction 6.2. Key Insights 6.3. Global Generic Injectables Market Size and Forecast, by Product Type 6.3.1. Large Molecule Injectables 6.3.1.1. Monoclonal Antibodies (mAbs) 6.3.1.2. Insulin 6.3.1.3. Others 6.3.2. Small Molecule Injectables 6.4. Global Generic Injectables Market Analysis, by Product Type 6.5. Global Generic Injectables Market Attractiveness Analysis, by Product Type 7. Global Generic Injectables Market Analysis, by Container Type 7.1. Introduction 7.2. Key Insights 7.3. Global Generic Injectables Market Size and Forecast, by Container Type 7.3.1. Vials 7.3.2. Premix 7.3.3. Prefilled Syringes 7.3.4. Ampoules 7.3.5. Other 7.4. Global Generic Injectables Market Analysis, by Container Type 7.5. Global Generic Injectables Market Attractiveness Analysis, by Container Type 8. Global Generic Injectables Market Analysis, by Application 8.1. Introduction 8.2. Key Insights 8.3. Global Generic Injectables Market Size and Forecast, by Application 8.3.1. Oncology 8.3.2. Infectious diseases 8.3.3. Cardiology 8.3.4. Diabetes 8.3.5. Immunology 8.3.6. Others 8.4. Global Generic Injectables Market Analysis, by Application 8.5. Global Generic Injectables Market Attractiveness Analysis, by Application 9. Global Generic Injectables Market Analysis, by Route of Administration 9.1. Introduction 9.2. Key Insights 9.3. Global Generic Injectables Market Size and Forecast, by Route of Administration 9.3.1. Intravenous 9.3.2. Intramuscular 9.3.3. Subcutaneous 9.3.4. Others 9.4. Global Generic Injectables Market Analysis, by Route of Administration 9.5. Global Generic Injectables Market Attractiveness Analysis, by Route of Administration 10. Global Generic Injectables Market Analysis, by Region 10.1. Introduction 10.2. Key Insights 10.3. Global Generic Injectables Market Size and Forecast, by Region, 2015-2032 10.3.1. North America 10.3.2. Europe 10.3.3. Asia Pacific 10.3.4. Latin America 10.3.5. Middle East & Africa 10.4. Global Generic Injectables Market Analysis, by Region 10.5. Global Generic Injectables Market Attractiveness Analysis, by Region 11. North America Generic Injectables Market Analysis 11.1. North America Generic Injectables Market Key Findings 11.2. North America Generic Injectables Market Overview 11.3. North America Generic Injectables Market Size and Forecast, by Product Type 11.3.1. Large Molecule Injectables 11.3.1.1. Monoclonal Antibodies (mAbs) 11.3.1.2. Insulin 11.3.1.3. Others 11.3.2. Small Molecule Injectables 11.3.3. North America Generic Injectables Market Analysis, by Product Type 11.4. North America Generic Injectables Market Size and Forecast, by Container Type 11.4.1. Vials 11.4.2. Premix 11.4.3. Prefilled Syringes 11.4.4. Ampoules 11.4.5. Other 11.5. North America Generic Injectables Market Size and Forecast, by Application 11.5.1. Oncology 11.5.2. Infectious diseases 11.5.3. Cardiology 11.5.4. Diabetes 11.5.5. Immunology 11.5.6. Others 11.6. North America Generic Injectables Market Size and Forecast, by Route of Administration 11.6.1. Intravenous 11.6.2. Intramuscular 11.6.3. Subcutaneous 11.6.4. Others 11.7. North America Generic Injectables Market Forecast, by Country 11.7.1. U.S. 11.7.2. Canada 11.8. North America Generic Injectables Market Attractiveness Analysis 11.8.1. By Product Type 11.8.2. By Container Type 11.8.3. By Application 11.8.4. By Route of Administration 11.8.5. By Country 12. Europe Generic Injectables Market Analysis 12.1. Europe Generic Injectables Market Key Findings 12.2. Europe Generic Injectables Market Overview 12.3. Europe Generic Injectables Market Size and Forecast, by Product Type 12.3.1. Large Molecule Injectables 12.3.1.1. Monoclonal Antibodies (mAbs) 12.3.1.2. Insulin 12.3.1.3. Others 12.3.2. Small Molecule Injectables 12.4. Europe Generic Injectables Market Size and Forecast, by Container Type 12.4.1. Vials 12.4.2. Premix 12.4.3. Prefilled Syringes 12.4.4. Ampoules 12.4.5. Other 12.5. Europe Generic Injectables Market Size and Forecast, by Application 12.5.1. Oncology 12.5.2. Infectious diseases 12.5.3. Cardiology 12.5.4. Diabetes 12.5.5. Immunology 12.5.6. Others 12.6. Europe Generic Injectables Market Size and Forecast, by Route of Administration 12.6.1. Intravenous 12.6.2. Intramuscular 12.6.3. Subcutaneous 12.6.4. Others 12.7. Europe Generic Injectables Market Forecast, by Country 12.7.1. Germany 12.7.2. U.K. 12.7.3. France 12.7.4. Spain 12.7.5. Italy 12.7.6. Rest of Europe 12.8. Europe Generic Injectables Market Attractiveness Analysis 12.8.1. By Product Type 12.8.2. By Container Type 12.8.3. By Application 12.8.4. By Route of Administration 12.8.5. By Country 13. Asia Pacific Generic Injectables Market Analysis 13.1. Asia Pacific Generic Injectables Market Key Findings 13.2. Asia Pacific Generic Injectables Market Overview 13.3. Asia Pacific Cytometry Market Size and Forecast, by Product Type 13.3.1. Large Molecule Injectables 13.3.1.1. Monoclonal Antibodies (mAbs) 13.3.1.2. Insulin 13.3.1.3. Others 13.3.2. Small Molecule Injectables 13.4. Asia Pacific Generic Injectables Market Size and Forecast, by Container Type 13.4.1. Vials 13.4.2. Premix 13.4.3. Prefilled Syringes 13.4.4. Ampoules 13.4.5. Other 13.5. Asia Pacific Generic Injectables Market Size and Forecast, by Application 13.5.1. Oncology 13.5.2. Infectious diseases 13.5.3. Cardiology 13.5.4. Diabetes 13.5.5. Immunology 13.5.6. Others 13.6. Asia Pacific Generic Injectables Market Size and Forecast, by Route of Administration 13.6.1. Intravenous 13.6.2. Intramuscular 13.6.3. Subcutaneous 13.6.4. Others 13.7. Asia Pacific Generic Injectables Market Forecast, by Country 13.7.1. China 13.7.2. India 13.7.3. Japan 13.7.4. Australia & New Zealand 13.7.5. Rest of Asia Pacific 13.8. Asia Pacific Generic Injectables Market Attractiveness Analysis 13.8.1. By Product Type 13.8.2. By Container Type 13.8.3. By Application 13.8.4. By Route of Administration 13.8.5. By Country 14. Latin America Generic Injectables Market Analysis 14.1. Latin America Generic Injectables Market Key Findings 14.2. Latin America Generic Injectables Market Overview 14.3. Latin America Cytometry Market Size and Forecast, by Product Type 14.3.1. Large Molecule Injectables 14.3.1.1. Monoclonal Antibodies (mAbs) 14.3.1.2. Insulin 14.3.1.3. Others 14.3.2. Small Molecule Injectables 14.4. Latin America Generic Injectables Market Size and Forecast, by Container Type 14.4.1. Vials 14.4.2. Premix 14.4.3. Prefilled Syringes 14.4.4. Ampoules 14.4.5. Other 14.5. Latin America Generic Injectables Market Size and Forecast, by Application 14.5.1. Oncology 14.5.2. Infectious diseases 14.5.3. Cardiology 14.5.4. Diabetes 14.5.5. Immunology 14.5.6. Others 14.6. Latin America Generic Injectables Market Size and Forecast, by Route of Administration 14.6.1. Intravenous 14.6.2. Intramuscular 14.6.3. Subcutaneous 14.6.4. Others 14.7. Latin America Generic Injectables Market Forecast, by Country 14.7.1. Brazil 14.7.2. Mexico 14.7.3. Rest of Latin America 14.8. Latin America Generic Injectables Market Attractiveness Analysis 14.8.1. By Product Type 14.8.2. By Container Type 14.8.3. By Application 14.8.4. By Route of Administration 14.8.5. By Country 15. Middle East & Africa Generic Injectables Market Analysis 15.1. Middle East & Africa Generic Injectables Market Key Findings 15.2. Middle East & Africa Generic Injectables Market Overview 15.3. Middle East & Africa Cytometry Market Size and Forecast, by Product Type 15.3.1. Large Molecule Injectables 15.3.1.1. Monoclonal Antibodies (mAbs) 15.3.1.2. Insulin 15.3.1.3. Others 15.3.2. Small Molecule Injectables 15.4. Middle East & Africa Generic Injectables Market Size and Forecast, by Container Type 15.4.1. Vials 15.4.2. Premix 15.4.3. Prefilled Syringes 15.4.4. Ampoules 15.4.5. Other 15.5. Middle East & Africa Generic Injectables Market Size and Forecast, by Application 15.5.1. Oncology 15.5.2. Infectious diseases 15.5.3. Cardiology 15.5.4. Diabetes 15.5.5. Immunology 15.5.6. Others 15.6. Middle East & Africa Generic Injectables Market Size and Forecast, by Route of Administration 15.6.1. Intravenous 15.6.2. Intramuscular 15.6.3. Subcutaneous 15.6.4. Others 15.7. Middle East & Africa Generic Injectables Market Size and Forecast, by Country 15.7.1. GCC Countries 15.7.2. Israel 15.7.3. South Africa 15.7.4. Rest of Middle East & Africa 15.8. Middle East Generic Injectables Market Attractiveness Analysis 15.8.1. By Product Type 15.8.2. By Container Type 15.8.3. By Application 15.8.4. By Route of Administration 15.8.5. By Country 16. Competition Landscape 16.1. Global Generic Injectables Market Share Analysis, by Company (2021) 16.2. Company Profiles 16.2.1. Pfizer Inc. 16.2.1.1. Overview (HQ, Employee Strength, Business Segments) 16.2.1.2. Financials 16.2.1.3. Recent Developments 16.2.1.4. Strategy 16.2.2. Novartis AG (Sandoz International GmbH) 16.2.2.1. Overview (HQ, Employee Strength, Business Segments) 16.2.2.2. Financials 16.2.2.3. Recent Developments 16.2.2.4. Strategy 16.2.3. Baxter 16.2.3.1. Overview (HQ, Employee Strength, Business Segments) 16.2.3.2. Financials 16.2.3.3. Recent Developments 16.2.3.4. Strategy 16.2.4. Fresenius SE & Co. KGaA 16.2.4.1. Overview (HQ, Employee Strength, Business Segments) 16.2.4.2. Financials 16.2.4.3. Recent Developments 16.2.4.4. Strategy 16.2.5. Mylan N.V. 16.2.5.1. Overview (HQ, Employee Strength, Business Segments) 16.2.5.2. Financials 16.2.5.3. Recent Developments 16.2.5.4. Strategy 16.2.6. Teva Pharmaceutical Industries Ltd. 16.2.6.1. Overview (HQ, Employee Strength, Business Segments) 16.2.6.2. Financials 16.2.6.3. Recent Developments 16.2.6.4. Strategy 16.2.7. Hikma Pharmaceuticals PLC. 16.2.7.1. Overview (HQ, Employee Strength, Business Segments) 16.2.7.2. Financials 16.2.7.3. Recent Developments 16.2.7.4. Strategy 16.2.8. Lupin Ltd. 16.2.8.1. Overview (HQ, Employee Strength, Business Segments) 16.2.8.2. Financials 16.2.8.3. Recent Developments 16.2.8.4. Strategy 16.2.9. Sanofi 16.2.9.1. Overview (HQ, Employee Strength, Business Segments) 16.2.9.2. Financials 16.2.9.3. Recent Developments 16.2.9.4. Strategy 16.2.10. Biocon 16.2.10.1. Overview (HQ, Employee Strength, Business Segments) 16.2.10.2. Financials 16.2.10.3. Recent Developments 16.2.10.4. Strategy
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 2: Global Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 3: Global Generic Injectables Market Size (US$ Mn) Analysis, by Large Molecule Injectables, 2015-2021
Table 4: Global Generic Injectables Market Size (US$ Mn) Forecast, by Large Molecule Injectables, 2022-2032
Table 5: Global Generic Injectables Market Size (US$ Mn) Analysis, by Small Molecule Injectables, 2015-2021
Table 6: Global Generic Injectables Market Size (US$ Mn) Forecast, by Small Molecule Injectables, 2022-2032
Table 7: Global Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 8: Global Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 9: Global Generic Injectables Market Size (US$ Mn) Analysis, by Vials, 2015-2021
Table 10: Global Generic Injectables Market Size (US$ Mn) Forecast, by Vials, 2022-2032
Table 11: Global Generic Injectables Market Size (US$ Mn) Analysis, by Ampoules, 2015-2021
Table 12: Global Generic Injectables Market Size (US$ Mn) Forecast, by Ampoules, 2022-2032
Table 13: Global Generic Injectables Market Size (US$ Mn) Analysis, by Premix, 2015-2021
Table 14: Global Generic Injectables Market Size (US$ Mn) Forecast, by Premix, 2022-2032
Table 15: Global Generic Injectables Market Size (US$ Mn) Analysis, by Prefilled syringes, 2015-2021
Table 16: Global Generic Injectables Market Size (US$ Mn) Forecast, by Prefilled syringes, 2022-2032
Table 17: Global Generic Injectables Market Size (US$ Mn) Analysis, by Others, 2015-2021
Table 18: Global Generic Injectables Market Size (US$ Mn) Forecast, by Others, 2022-2032
Table 19: Global Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 20: Global Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 21: Global Generic Injectables Market Size (US$ Mn) Analysis, by Infectious diseases, 2015-2021
Table 22: Global Generic Injectables Market Size (US$ Mn) Forecast, by Infectious diseases, 2022-2032
Table 23: Global Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 24: Global Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 25: Global Generic Injectables Market Size (US$ Mn) Analysis, by Intravenous, 2015-2021
Table 26: Global Generic Injectables Market Size (US$ Mn) Forecast, by Intravenous, 2022-2032
Table 27: Global Generic Injectables Market Size (US$ Mn) Analysis, by Intramuscular, 2015-2021
Table 28: Global Generic Injectables Market Size (US$ Mn) Forecast, by Intramuscular, 2022-2032
Table 29: Global Generic Injectables Market Size (US$ Mn) Analysis, by Subcutaneous, 2015-2021
Table 30: Global Generic Injectables Market Size (US$ Mn) Forecast, by Subcutaneous, 2022-2032
Table 31: Global Generic Injectables Market Size (US$ Mn) Analysis, by Region, 2015-2021
Table 32: Global Generic Injectables Market Size (US$ Mn) Forecast, by Region, 2022-2032
Table 33: North America Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 34: North America Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 35: North America Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 36: North America Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 37: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 38: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 39: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 40: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 41: North America Generic Injectables Market Size (US$ Mn) Analysis, by Country, 2015-2021
Table 42: North America Generic Injectables Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 43: Europe Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 44: Europe Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 45: Europe Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 46: Europe Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 47: Europe Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 48: Europe Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 49: Europe Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 50: Europe Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 51: Europe Generic Injectables Market Size (US$ Mn) Analysis, by Country, 2015-2021
Table 52: Europe Generic Injectables Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 53: Asia Pacific Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 54: Asia Pacific Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 55: Asia Pacific Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 56: Asia Pacific Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 57: Asia Pacific Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 58: Asia Pacific Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 59: Asia Pacific Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 60: Asia Pacific Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 61: Asia Pacific Generic Injectables Market Size (US$ Mn) Analysis, by Country, 2015-2021
Table 62: Asia Pacific Generic Injectables Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 63: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 64: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 65: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 66: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 67: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 68: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 69: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 70: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 71: Latin America Generic Injectables Market Size (US$ Mn) Analysis, by Country, 2015-2021
Table 72: Latin America Generic Injectables Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 73: MEA Generic Injectables Market Size (US$ Mn) Analysis, by Product Type, 2015-2021
Table 74: MEA Generic Injectables Market Size (US$ Mn) Forecast, by Product Type, 2022-2032
Table 75: MEA Generic Injectables Market Size (US$ Mn) Analysis, by Container Type, 2015-2021
Table 76: MEA Generic Injectables Market Size (US$ Mn) Forecast, by Container Type, 2022-2032
Table 77: MEA Generic Injectables Market Size (US$ Mn) Analysis, by Application, 2015-2021
Table 78: MEA Generic Injectables Market Size (US$ Mn) Forecast, by Application, 2022-2032
Table 79: MEA Generic Injectables Market Size (US$ Mn) Analysis, by Route of Administration, 2015-2021
Table 80: MEA Generic Injectables Market Size (US$ Mn) Forecast, by Route of Administration, 2022-2032
Table 81: MEA Generic Injectables Market Size (US$ Mn) Analysis, by Country, 2015-2021
Table 82: MEA Generic Injectables Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 83: U.S. Generic Injectables Market Size (US$ Mn), 2022-2032
Table 84: Canada Generic Injectables Market Size (US$ Mn), 2022-2032
Table 85: Brazil Generic Injectables Market Size (US$ Mn), 2022-2032
Table 86: Mexico Generic Injectables Market Size (US$ Mn), 2022-2032
Table 87: Argentina Generic Injectables Market Size (US$ Mn), 2022-2032
Table 88: Germany Generic Injectables Market Size (US$ Mn), 2022-2032
Table 89: France Generic Injectables Market Size (US$ Mn), 2022-2032
Table 90: Italy Generic Injectables Market Size (US$ Mn), 2022-2032
Table 91: Spain Generic Injectables Market Size (US$ Mn), 2022-2032
Table 92: U.K. Generic Injectables Market Size (US$ Mn), 2022-2032
Table 93: Benelux Generic Injectables Market Size (US$ Mn), 2022-2032
Table 94: Russia Generic Injectables Market Size (US$ Mn), 2022-2032
Table 95: China Generic Injectables Market Size (US$ Mn), 2022-2032
Table 96: Japan Generic Injectables Market Size (US$ Mn), 2022-2032
Table 97: South Korea Generic Injectables Market Size (US$ Mn), 2022-2032
Table 98: India Generic Injectables Market Size (US$ Mn), 2022-2032
Table 99: Thailand Generic Injectables Market Size (US$ Mn), 2022-2032
Table 100: Indonesia Generic Injectables Market Size (US$ Mn), 2022-2032
Table 101: Malaysia Generic Injectables Market Size (US$ Mn), 2022-2032
Table 102: Australia & New Zealand Generic Injectables Market Size (US$ Mn), 2022-2032
Table 103: GCC Countries Generic Injectables Market Size (US$ Mn), 2022-2032
Table 104: Egypt Generic Injectables Market Size (US$ Mn), 2022-2032
Table 105: South Africa Generic Injectables Market Size (US$ Mn), 2022-2032
Table 106: Turkey Generic Injectables Market Size (US$ Mn), 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Generic Injectables Market Snapshot
Figure 2: Global Generic Injectables Market Size Value (US$ Mn) Forecast, 2022-2032
Figure 3: Market Value Share (%), by Product Type (2021)
Figure 4: Market Value Share (%), by Container Type (2021)
Figure 5: Market Value Share (%), by Route of Administration (2021)
Figure 6: Market Value Share (%), by Application (2021)
Figure 7: Global Generic Injectables Market Value Share analysis (%), by Product Type, 2022 and 2032
Figure 8: Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2022-2032
Figure 9: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Large Molecule Injectables, 2022-2032
Figure 10: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Small Molecule Injectables, 2022-2032
Figure 11: Global Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 12: Global Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 13: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vials, 2022-2032
Figure 14: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ampoules, 2022-2032
Figure 15: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Premixes, 2022-2032
Figure 16: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Prefilled Syringes, 2022-2032
Figure 17: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2032
Figure 18: Global Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 19: Global Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 20: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diabetes, 2022-2032
Figure 21: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Infectious diseases, 2022-2032
Figure 22: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cardiology, 2022-2032
Figure 23: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diabetes, 2022-2032
Figure 24: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Immunology, 2022-2032
Figure 25: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2032
Figure 26: Global Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 27: Global Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Figure 28: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intravenous, 2022-2032
Figure 29: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intramuscular, 2022-2032
Figure 30: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Subcutaneous, 2022-2032
Figure 31: Global Generic Injectables Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2032
Figure 32: Global Generic Injectables Market Value Share (%), by Region, 2022 and 2032
Figure 33: Global Generic Injectables Market Attractiveness, by Region, 2022-2032
Figure 34: North America Generic Injectables Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 35: North America Generic Injectables Market Value Share Analysis, by Country, 2022 and 2032
Figure 36: North America Generic Injectables Market Attractiveness Analysis, by Country, 2015-2032
Figure 37: North America Generic Injectables Market Value Share (%), by Product Type, 2022 and 2032
Figure 38: North America Generic Injectables Market Attractiveness, by Product Type, 2022-2032
Figure 39: North America Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 40: North America Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 41: North America Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 42: North America Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 43: North America Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 44: North America Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Figure 45: Europe Generic Injectables Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 46: Europe Generic Injectables Market Value Share Analysis, by Country, 2022 and 2032
Figure 47: Europe Generic Injectables Market Attractiveness Analysis, by Country, 2015-2032
Figure 48: Europe Generic Injectables Market Value Share (%), by Product Type, 2022 and 2032
Figure 49: Europe Generic Injectables Market Attractiveness, by Product Type, 2022-2032
Figure 50: Europe Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 51: Europe Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 52: Europe Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 53: Europe Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 54: Europe Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 55: Europe Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Figure 56: Asia Pacific Generic Injectables Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 57: Asia Pacific Generic Injectables Market Value Share Analysis, by Country, 2022 and 2032
Figure 58: Asia Pacific Generic Injectables Market Attractiveness Analysis, by Country, 2015-2032
Figure 59: Asia Pacific Generic Injectables Market Value Share (%), by Product Type, 2022 and 2032
Figure 60: Asia Pacific Generic Injectables Market Attractiveness, by Product Type, 2022-2032
Figure 61: Asia Pacific Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 62: Asia Pacific Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 63: Asia Pacific Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 64: Asia Pacific Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 65: Asia Pacific Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 66: Asia Pacific Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Figure 67: Latin America Generic Injectables Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 68: Latin America Generic Injectables Market Value Share Analysis, by Country, 2022 and 2032
Figure 69: Latin America Generic Injectables Market Attractiveness Analysis, by Country, 2015-2032
Figure 70: Latin America Generic Injectables Market Value Share (%), by Product Type, 2022 and 2032
Figure 71: Latin America Generic Injectables Market Attractiveness, by Product Type, 2022-2032
Figure 72: Latin America Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 73: Latin America Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 74: Latin America Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 75: Latin America Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 76: Latin America Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 77: Latin America Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Figure 78: Middle East & Africa Generic Injectables Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 79: Middle East & Africa Generic Injectables Market Value Share Analysis, by Country, 2022 and 2032
Figure 80: Middle East & Africa Generic Injectables Market Attractiveness Analysis, by Country, 2015-2032
Figure 81: Middle East & Africa Generic Injectables Market Value Share (%), by Product Type, 2022 and 2032
Figure 82: Middle East & Africa Generic Injectables Market Attractiveness, by Product Type, 2022-2032
Figure 83: Middle East & Africa Generic Injectables Market Value Share (%), by Container Type, 2022 and 2032
Figure 84: Middle East & Africa Generic Injectables Market Attractiveness, by Container Type, 2022-2032
Figure 85: Middle East & Africa Generic Injectables Market Value Share (%), by Application, 2022 and 2032
Figure 86: Middle East & Africa Generic Injectables Market Attractiveness, by Application, 2022-2032
Figure 87: Middle East & Africa Generic Injectables Market Value Share (%), by Route of Administration, 2022 and 2032
Figure 88: Middle East & Africa Generic Injectables Market Attractiveness, by Route of Administration, 2022-2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the market worth for Generic Injectables in 2021?
As of 2021, Fact.MR estimated the generic injectables market to have reached US$ 800 Million
What is the expected worth of the generic injectables industry in 2022?
By 2022, Fact.MR expected demand for generic injectables to reach US$ 1.02 Billion
At what rate did the generic injectables market flourish from 2015-2021?
From 2015-2021, the Generic Injectables market grew at a 13.1% value CAGR
What is the expected forecast CAGR for generic injectables from 2022-2032?
From 2022-2032, generic injectables demand is likely to surge at a 13.3% CAGR
At what value will the market for generic injectables close in 2032?
By 2032, the market for generic injectables is likely to be valued at US$ 3.6 Billion
What is the expected market value for the U.S generic injectables market?
By 2032, Fact.MR expects the U.S market for generic injectables to reach US$ 250 Million
How opportunistic is the Chinese market for Generic Injectables?
China is expected to register a 16.1% CAGR in the generic injectables industry
What are the expected growth rates for the South Korean and Japanese markets?
South Korea and Japan are expected to document CAGRs worth 12.1% and 15.3% respectively in the generic injectables market
Which Product type will account for the maximum generic injectables revenue?
Large molecular generic injectables will be maximum, expanding at a 6.4% CAGR
By application, which category is likely to remain top-selling until 2032?
Generic injectables for oncology segment will remain most preferred, expanding at a CAGR of 11.5% until 2032
Generic Injectables Market